Permetrexed as second-line therapy for advanced non-small-cell lung cancer (NSCLC)

E. Felip, R. Rosell

Research output: Contribution to journalArticleResearch

12 Citations (Scopus)
Original languageEnglish
Pages (from-to)579-85
JournalTherapy Clinical Risk Management
Volume4
Publication statusPublished - 1 Jan 2008

Cite this